Posted by AGORACOM-JC
at 10:21 AM on Monday, October 5th, 2020
Entered into a blockchain development agreement with a client in the General Data Protection Regulation compliance space
The initial phase of the Agreement is valued at approximately $50,000 and will last for approximately four weeks
TORONTO, Oct. 05, 2020 — Blockchain Foundry Inc. (“BCF” or the “Company”) (CSE:BCFN), a leading North American blockchain development firm, has entered into a blockchain development agreement (the “Agreement”) with a client (the “Client”) in the General Data Protection Regulation (“GDPR”) compliance space. The initial phase of the Agreement is valued at approximately $50,000 and will last for approximately four weeks.
GDPR is a regulation in EU law concerning data protection and privacy. The market for GDPR compliance services in Europe is estimated to be worth approximately US$1.2 billion by 2023 1 .
Pursuant to the Agreement, BCF will work with the Client to complete the MVP of its GDPR compliance solution. The Client expects to undertake more product development beyond the MVP phase and BCF will have the opportunity to establish itself as the preferred vendor for future development initiatives.
About Blockchain Foundry Inc.
Blockchain Foundry develops and commercializes blockchain-based business solutions and provides consulting services to corporate clients seeking to incorporate blockchain technology into their businesses.
Certain portions of this press release contain “forward-looking information” within the meaning of applicable Canadian securities legislation, which is also referred to as “forward-looking statements”, which may not be based on historical fact. Wherever possible, words such as “will,” “plans,” “expects,” “targets,” “continues,” “estimates,” “scheduled,” “anticipates,” “believes,” “intends,” “may,” “could,” “would” or might, and the negative of such expressions or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved, have been used to identify forward-looking information.
Forward-looking statements should not be read as guarantees of future events, future performance or results, and will not necessarily be accurate indicators of the times at, or by which, such events, performance or results will be achieved, if achieved at all. Readers should not place undue reliance on such forward-looking statements, as they reflect management’s current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BCF are inherently subject to significant business, economic, regulatory, competitive, political and social uncertainties, and contingencies. Many factors could cause BCF’s actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements.
Posted by AGORACOM-JC
at 9:37 AM on Monday, October 5th, 2020
InnoCan Pharma (INNO:CSE) Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids. InnoCan has 3 fully operating divisions to address the market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. Learn more.
How Richard Carleton Is Leading The Cannabis Revolution At The CSE
Cannabis has emerged as a viable commodity for international trade, and the Canadian Stock Exchange is leading the charge.
A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations
InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes
This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.
The growing cannabis market
As the cannabis industry continues to advance, more and more companies are moving to get their stocks listed on Canada Securities Exchange. Cannabis is no longer just a plant. The debate on its legality, decriminalization, health benefits, among others, are now the main focus of attention. Cannabis has emerged as a viable commodity for international trade, and raw material for consumption, with several companies listed on the stock market and shareholders who speculate on its rise or fall according to news of its legalization in more corners.
A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations. InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes. This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.
Although the debate will always be present, more and more countries have chosen to decriminalize and even promote the use of cannabis, especially for medicinal purposes. The likes of Germany, Argentina, Italy, Canada, etc already allow the use of CBD derivatives to treat health problems, always under medical prescription, but often even facilitating their access to patients.
Cannabis for recreational activities is now an emerging discourse, and borders that seemed immovable a while ago have been crossed. Canada passed a regulation in 2018 that made it one of the few countries that fully allowed recreational consumption and the first of the G-8.
It thus joined Uruguay, a country that has always had a fairly permissive position. And the Netherlands, which despite the fame of its cannabis sale in coffee shops, has not changed its regulation in recent years (The Netherlands does not allow cultivation for self-consumption). As well as Mexico, who in a wide debate in recent years, have legalized marijuana for medical use. In the United States, almost 30 of its states have opened the door to medicinal consumption, and about 10 of them, including California, to recreational use.
The growth of the marijuana-related market has exploded in recent years and according to GlobeNewswire, “The global legal marijuana market size is expected to reach USD 73.6 billion by 2027.” This includes medicinal, recreational, and derivatives.
Furthermore, “It is anticipated to expand at a CAGR of 18.1% during the forecast period. The increasing legalization of cannabis for medical as well as adult-use is expected to promote growth. Based on type, the medical segment held the leading revenue share of 71% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson’s disease, and Alzheimer’s disease among other neurological conditions. Moreover, an increasing need for pain management therapies along with the growing disease burden of chronic pain among elders is expected to boost the product demand.”
In this context, in recent years numerous companies, especially in the pharmaceutical industry, have begun to fully immerse themselves in this buoyant market with the expectation that over time it will become increasingly legal in more countries. Most of these companies are Canadian, and they have emerged in the glow of the country’s decriminalization momentum.
Some are dedicated to distribution for recreational consumption, those that lean more to the medical side, and those that are specializing in derivatives. Several things unite them: they are all Canadian for their reference in legalization, they are all growing, and a lot of them have successfully been listed on the stock market.
Without a doubt, the Canadian Securities Exchange (CSE) has played a vital role in strengthening the marijuana-related market in Canada. Led by a visionary CEO, Richard Carleton, it has emerged as one of the pillars of cannabis investment in the country. Exchange operators have critically guided affairs, bringing about the availability of a variety of investment options for cannabis investors.
The CSE is Canada’s fastest-growing stock exchange. With more than 600 listings and a cumulative market capitalization of approximately C$23 billion, the Exchange continues to attract entrepreneurial companies that are looking for the most efficient path to the North American capital markets. With the help of the Canada Securities Exchange, Canadian companies can choose to test the waters outside Canada, particularly in the United States, as long as they can allay the fears of shareholders. Presently, cannabis is illegal on a federal level in the USA, however, it is legal for medical and recreational purposes in a good number of states.
The Canadian Securities Exchange (CSE) is the go-to platform for cannabis companies who are still developing. It offers much-needed exposure for the growth of these emerging companies, while also giving established organizations, such as multi-state operators in the US, a chance to gain a competitive advantage in the global market.
According to Richard Carleton, “It is always gratifying to see companies capitalizing on opportunities in the public market to pursue their vision for growth. The CSE has a mandate to facilitate entrepreneurial activity such as this.”
Looking at the medical aspect, he further believes that large and small companies have complementary roles in the pharmaceutical industry. Start-up companies play an important role in conducting early research and development in identifying new drug therapies. History shows that a lot of value creation happens in this space before the drugs are taken through clinical trials and ultimately brought to the market by the pharma giants and are prescribed to patients worldwide. In addition, regardless of their size, pharma companies need to have exceptional technical and logistical talent to develop a drug and move it through regulated trials.
Presently, there is a tremendous amount of effort in the pursuit of therapies and vaccines for COVID-19. This recent activity is a good reminder of how powerful the public markets are at organizing capital to solve real-world issues. You can be sure that whatever health challenge society is presented with next, the market will be here to find solutions.
Posted by AGORACOM-JC
at 7:18 AM on Monday, October 5th, 2020
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com
VANCOUVER, BC / October 5, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), a developer of plant-based alternatives to dairy-based baby nutrition today announced that [Hamutal Yitzhak], [CEO], will present at VirtualInvestorConferences.com on October 8th.
Current US distribution agreements and updated plans for retail rollout.
H&H Global Group, company’s largest investor increased their stake in the last round of financing, and the new territories distribution and expansion plans.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
About Virtual Investor Conferences® Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.
A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access. Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
For more information, contact:
Ms. Hamutal Yitzhak, CEO, Co-Founder & Director ELSE Nutrition Holdings Inc. E: [email protected] P: +972(0)3-6445095
Mr. Sokhie Puar, Director of Else Nutrition Email: [email protected] Telephone: 604-603-7787
Virtual Investor Conferences
John M. Viglotti SVP Corporate Services, Investor Access OTC Markets Group (212) 220-2221 [email protected]
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will”, “expect” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that listing on the FSE will create additional liquidity and attract additional investors in the European market. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Posted by AGORACOM-JC
at 7:15 AM on Monday, October 5th, 2020
Announces the filing of provisional patent applications and various Trademark Registries for its contactless data applications
The filings come in the wake of both actual integrations with globally renowned customers and a substantial increase in demand from various verticals, including college sports, professional sports, hotels, TV & movie productions, and hospitality & entertainment, amongst others
VANCOUVER, British Columbia, Oct. 05, 2020 — Loop Insights Inc. (MTRX:TSXV OTCQB:RACMF) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive automated marketing, contact tracing, and contactless solutions to the brick and mortar space, announces the filing of provisional patent applications and various Trademark Registries for its contactless data applications. The filings come in the wake of both actual integrations with globally renowned customers and a substantial increase in demand from various verticals, including college sports, professional sports, hotels, TV & movie productions, and hospitality & entertainment, amongst others.
Loop’s venue tracing platform is unique in that it requires no app download and only a tap of the user’s device to check-in for protection and alerts. Loop’s SmarTap devices are installed at multiple points to log every individual that enters a venue by check-in using the Loop contact tracing wallet pass. Loop’s solution allows venue staff to quickly identify individuals that were in proximity to any infected person and isolate potentially infected individuals as quickly as possible for follow-up testing.
Moreover, Loop’s contactless ticketing and e-commerce solution adds a further layer of protection by removing this very manual process, while also delivering artificial intelligence driven marketing solutions to provide real-time personalized promotions and targeted engagement that reinvent the live customer experience.
As a result, Loop’s venue tracing and contactless solutions platform provides live event operators with the ability to safely reopen by transforming their venues into 100% digital and cashless environments with contactless entry, contactless payments, and never before seen customer engagement that not only resumes revenue-generating operations but expand them.
Rob Anson, CEO of Loop Insights, stated, “Interest in Loop’s integrated contactless platform for tracing, ticketing, targeting, and engagement by live event operators has been significant over the past couple of months as they desperately search for best of breed solutions that will allow them to safely restart operations and generate much needed revenue. Our turnkey contactless solutions platform has turned a lot of heads around the world, and we intend to capitalize on this opportunity, given how well-positioned we are to become a global leader.”
About Loop Insights: Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia.
This news release contains certain statements which constitute forward-looking statements or information.Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in thesecurities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 2:36 PM on Friday, October 2nd, 2020
Announced the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa, effective immediately
Additionally, Chantal Ward, RN has taken a permanent position with the Company as Director, Dermatological Services.
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), effective immediately. Additionally, Chantal Ward, RN has taken a permanent position with the Company as Director, Dermatological Services.
“Naman’s extensive background in healthcare and medical devices, along with his deep relationships will allow us to accelerate business development opportunities in the region,” said Mike Druhan, President of Dermatological Products & Services. “Chantal is an internationally recognized and respected leader in the dermatology and aesthetics spaces, bringing credibility to our offerings and putting an impressive opinion leader network at our disposal.”
Mr. Demaghlatrous has more than 20 years of experience in the healthcare industry, including roles with medical device and pharmaceutical companies leading business strategy, international product licensing, business development and operations. He has proven expertise in leading organizations through start-up to rapid growth, expansion and value creation with companies such as Medtronic, Pediapharm, Johnson & Johnson and Atfal Pharma. Mr. Demaghlatrous will play an integral part in MedX’s revenue growth prospects by securing European, Middle Eastern and African partnerships for MedX’s skin assessment telemedicine technology. Initially supporting the roll out and expansions in the Netherlands, Spain and Turkey, he will also be responsible for securing joint ventures and partnerships across the EMEA Region.
“Helping patients access an e-consult on suspicious lesions or moles quickly and easily means better treatment and better outcomes,” noted Mr. Demaghlatrous. “There is already significant interest and traction across the region and I am expecting substantial growth over the next six to nine months.”
Chantal Ward RN, a Diploma Nurse Graduate from an operating room background, has 20+ years’ experience as a clinical trainer of advanced medical aesthetic equipment and technology. Her expertise is acknowledged across Canada and around the world, where she has provided guidance and training to hundreds of medical aesthetic professionals. Ms. Ward is Co-Founder of Clarity MedSpa & Laser Centre, Toronto and has significant experience with MedX’s SIAscopy on DermSecure™.
“I have been using this device in my clinic for several years and have caught multiple melanomas,” said Ms. Ward. “The device is easy to use and the ability to have a dermatologist provide a remote e-consult, within 72 hours, is critical. Early detection is the key to a successful patient outcome.”
“MedX is in full commercialization mode and Naman and Chantal are welcomed additions to our team. Recently, Damon Goodwin and Nick Hoffman have been announced to our senior management team and we are already feeling their impact. It is a satisfying to know that MedX can attract such seasoned professionals and I strongly believe that is because of the strength of our technology offering and the culture we have built,” further commented Mr. Druhan.
Currently, between two and three million non-melanoma skin cancers and 300,000 melanoma skin cancers occur globally each year. One in every three cancers diagnosed is a skin cancer and, according to Skin Cancer Foundation statistics, one in every five people will develop skin cancer in their lifetime. The global demand for SIAscopy on DermSecure™ will continue to increase with the growth of telemedicine and as early detection is recognized as the way to optimize survival and reduce healthcare costs.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Mike Druhan, President, Dermatological Services MedX Health Corp Tel: 905-599-7852
Posted by AGORACOM-JC
at 4:46 PM on Thursday, October 1st, 2020
Announced the appointment of Steven Archambault, CPA, CA as the Company’s new Chief Financial Officer
Mr. Archambault brings a wealth of international finance experience to KWESST. With 15 years of public company experience, he has deep functional expertise and technical knowledge in all aspects of corporate finance, financial planning, and accounting, in addition to merger and acquisitions.
Mr. Archambault will commence immediately, replacing Paul Kania.
Ottawa, Ontario–(October 1, 2020) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced the appointment of Steven Archambault, CPA, CA as the Company’s new Chief Financial Officer.
Mr. Archambault brings a wealth of international finance experience to KWESST. With 15 years of public company experience, he has deep functional expertise and technical knowledge in all aspects of corporate finance, financial planning, and accounting, in addition to merger and acquisitions. Mr. Archambault will commence immediately, replacing Paul Kania.
Mr. Kania has been on contract as CFO since November 2019 to position the Company for its going public transaction and will remain available to KWESST as an advisor to facilitate the transition. David Luxton, Executive Chairman, thanked Mr. Kania on behalf of the board for his assistance in getting the Company to this milestone.
“We’re delighted to welcome Steven Archambault on board,” added Mr. Luxton. “He has the rare combination of experience and ability to contribute to the Company’s strategic agenda as well as ensure operational excellence as the Company grows from here.”
Steven Archambault commented, “I’m excited to be joining the KWESST leadership team at a time when the Company continues to gain traction with its disruptive technologies in the defence and security community, and the potential for outsized growth on a global scale with superior returns to shareholders.”
Mr. Archambault’s appointment will initially be on a part-time employment basis for the next six months with KWESST having the option to convert the employment to a full-time indefinite period.
In connection with his appointment, Mr. Archambault has been granted 250,000 options exercisable at a price of $0.75 until September 29, 2025.
Steven Archambault Bio
Mr. Archambault began his career as a CPA, CA with Ernst & Young LLP, followed by senior finance positions at AXIS Capital, a global insurer and reinsurer, and more recently had CFO roles with small cap public Canadian companies listed on the TSX-V and CSE in media broadcasting technology and health & wellness industries.
About KWESST
KWESST develops and commercializes high-value ultra-miniaturized technology applications that make a critical difference to the safety and operational effectiveness of personnel in the defence and security industries. The company’s current portfolio of unique proprietary offerings include: its signature TASCSTM (Tactical and Situational Control System) for real-time awareness and targeting information from any source (including drones) streamed directly to users’ smart devices and weapons; the autonomous Grey GhostTM soldier-portable micro drone missile system that defends against small hostile drones including swarms using high-speed kinetic impact; a Ground Laser Defence system to counter the emerging threat of weaponized lasers against personnel; and, the PhantomTM electronic battlefield decoy system to mask the electromagnetic signature of friendly forces with decoy signatures at false locations to deceive and confuse adversaries. All systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems including Frontline, Edge, Killswitch and ATAK (Android Tactical Assault Kit) among others. KWESST also has developmental “smart ordnance” projects including its “Shot Counter” system, which records the number and type of rounds fired, for optimized firearms maintenance and performance. The Company is headquartered in Ottawa, Canada, with representative offices in Washington, DC, London, UK and Abu Dhabi, UAE. KWESST trades on the TSX Venture Exchange under the symbol KWE.
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the timing for the commencement of trading and the plans and operations of KWESST after giving effect to the Qualifying Transaction. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. KWESST disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Posted by AGORACOM-JC
at 9:41 AM on Thursday, October 1st, 2020
Company has decided to continue down that path by announcing that it has entered into a non-binding letter of intent (the “LOI”) with Brujera Elixirs Inc. (“Brujera”) to formulate an exclusive line of 4 “Innovative adaptogenic mushroom-infused” beverage products for the natural health and wellness market.
Product development and steps for final formulation will commence immediately upon signing of the definitive agreement with Brujera; which is expected to occur on or before October 30, 2020
VANCOUVER, British Columbia, Oct. 01, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo Nutra” or the “Company”) Further to the Company’s news release dated May 22, 2020 announcing that Primo Nutra received its Natural Product Number (“NPN) from Health Canada, the Company has decided to continue down that path by announcing that it has entered into a non-binding letter of intent (the “LOI”) with Brujera Elixirs Inc. (“Brujera”) to formulate an exclusive line of 4 “Innovative adaptogenic mushroom-infused” beverage products for the natural health and wellness market.
Product development and steps for final formulation will commence immediately upon signing of the definitive agreement with Brujera; which is expected to occur on or before October 30, 2020.
The specific types of functional mushrooms which will be used in formulating Primo Nutra’s exclusive beverages will be: Reishi, Cordyceps, Lion’s Mane and Chaga.
The Company was granted its first NPN(80099466) on May 22, 2020 for their lemon hand sanitizer. Primo Nutra will be focused on introducing 8 different natural health products to Canada’s health and wellness market.
AboutBrujeraElixirs Inc.
Launched by award winning B.C. master mixologist, sommelier and entrepreneur Kelly Ann Woods, Brujera is a house of brands which currently includes Boozewitch (sober-curious mixers) and State B Cannabis Beverage Co.Ms. Woods is an entrepreneur who has founded multiple companies in the CBD, cannabis, alcohol and non-alcohol beverage industry. In the last year, Kelly was named the 2019 RBC Canadian Woman Entrepreneur of the Year Award for Micro -Business Award ( https://www.youtube.com/watch?v=oLi9JSnhJ64 ). Woman of the Year from BC Business in addition to a CANIE Woman Entrepreneur award.
Nicknamed the “Boozewitch,” Quebec-born Kelly attended CEGEP in Montreal with a focus on theatre and worked as a flight attendant for Air Canada before moving to the West Coast. She spent years honing her drinks skills as a sommelier and doing hospitality work, all the while experimenting with beverage formulation. She is actively bringing a cannabis beverage to the US and Canadian markets under the name State B and opening an oceanfront wine bar in Squamish with a team of accomplished women in hospitality.
TERMS OF THE TRANSACTION
The LOI was signed on July 14, 2020. Pursuant to the LOI Primo Nutra and Brujera will seek to enter into a Definitive Consulting Agreement whereby Primo Nutra will create white label mushroom infused drinks for distribution in Canada and international markets while Brujera will create unique exclusive formulations for Primo Nutra’s mushroom-infused energy shot drinks.
Richard Cindric, CEOof PrimoComments:
“Ms. Woods experience in formulating functional CBD, cannabis, and alcoholic beverages is what we are looking for in a white-label partner. We are confident she is the right partner to introduce a mushroom based energy drink to compete with brands like Boost and Ensure. We are in a better position now than a year ago to peruse a line of energy drinks, as it was important to get a NPN number from Health Canada first.”
Kelly Ann Woods, CEO of BRUJERA Comments:
“We are pleased to be aligning ourselves with Primo for this line of adaptogenic mushroom drinks. At a time when immunity and cognitive function are at the forefront of people’s minds, this product is sure to be one in many people’s daily regime.”
Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its NPN and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.
On behalf of the Board of Directors
PRIMO NUTRACEUTICALS INC.
“ Andy Jagpal ”
Andy Jagpal President and Director
For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected] .
To learn more about what this news means to the shareholders visit:
FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.
Posted by AGORACOM-JC
at 9:17 AM on Thursday, October 1st, 2020
If you haven’t heard of KWESST Micro Systems (KWE:TSXV) you’re not alone because the Company just listed for trading a couple of weeks ago – and it is probably the coolest new listing of 2020 if you love high-tech, covert defense systems that we only get to see in Tom Cruise movies.
KWESST is a leader in “soldier systems” which are technologies that increase the capabilities of soldiers, Let’s be clear right off the start, KWESST doesn’t sell weaponry. Rather, it sells technologies that make a big difference to the safety and effectiveness of soldiers.
For example, out in a field of combat, soldiers emit Electro Magnetic (EM) signatures that make them detectable by enemy combatants. KWESST has a battlefield decoy system that creates multiple false phantom signatures to spoof adversaries. This picture is worth 1,000 words.
We could go on about many other such technologies created by KWESST but this is AGORACOM after all and we want to get down to the business of KWESST, the highlights of which are as follows:
A developer of next-generation systems for forces around the world, including those of NATO and its allies
A leadership team whose experience spans decades and hundreds of millions of dollars in military and homeland security contracts
A sales and distribution network of agents that spans the globe
Partnerships with globally recognized OEM’s, including Samsung
A sales pipeline that stands at $93,000,000 (not a typo) as of August 2020
Already generating revenues in 2020
And last but not least, a secret weapon in its Executive Chairman David Luxton, whose companies under his leadership have generated over $1,000,000,000 (Yes, BILLION).
The soldier systems market is projected to hit $14.5 Billion by 2023 and, up until now, small cap investors have never had a company to participate in this lucrative (and SUPER COOL) market.
Now you do. Meet KWESST Micro Systems. Watch this first ever interview with David Luxton himself to learn about where KWESST is going.
Posted by AGORACOM-JC
at 5:24 PM on Wednesday, September 30th, 2020
HPQ Silicon Resources (HPQ:TSXV) is a Canadian producer of Silicon that is building a line of specialty silicon products needed for electric batteries.
More than just lip service, HPQ has already announced NDA’s with 2 undisclosed companies in the space and has hinted at other NDA’s that are so tight they could not even be announced.
5 YEARS ON THE SILICON ROAD LESS TRAVELED
Over the past 5 years, HPQ has teamed up with 2 world renowned technology partners to manufacture high purity silicon cleaner, cheaper and better than anyone in the world – because you can’t dig it out of the ground like other battery metals such as graphite, cobalt and nickel. Now HPQ is on the verge of sending samples of its industry leading silicon to NDA and other potential partners as early as December.
However, despite providing shareholders with a great return during this period, HPQ’s silicon strategy was still met by scepticism amongst investors who found it easier to understand traditional battery metal stories.
TESLA CHANGED EVERYTHING OVERNIGHT
This all changed 7 days ago on September 23rd 2020, when this headline emerged from Tesla’s “Battery Day”
“Tesla To Revolutionize Use Of Silicon In Batteries: Slash Costs, Increases Range”
With the specific references to Silicon + Cheaper Cost + Longer Range, you would have thought HPQ wrote this headline themselves given the fact this is EXACTLY what they have been telling the world for the last 5 years. Now, thanks to this headline, HPQ Silicon no longer has to convince everybody that Silicon is the holy grail of batteries …. Elon Musk and Tesla have done it for them in one fell swoop.
7 DAYS LATER, A GLOBAL AUTO MANUFACTURER COMES KNOCKING TO SECURE FIRST POSITION
This quote from CEO Bernard Tourillon says it all:
“To have piqued the interest of a major industrial player so early on, and to the point where they will pay for product before production just to secure a position, speaks volumes about where we are and what we are doing”
And this one from technology partner PyroGenesis Canada drives the point home:
“To receive this type of validation mere weeks after signing a Development Agreement with HPQ Silicon , and mere days after a major Battery Conference, which highlighted the importance of such products, is astounding. We are excited to see HPQ NANO effectively taking pre-orders from giants in the industry who, based on our experience, are not in the habit of wasting their time”
If you are serious about battery metals and electric vehicles entering a paradigm shifting parabolic stage in the next 5 years, then you owe it to yourself to watch this interview with CEO Bernard Tourillon.
Posted by AGORACOM-JC
at 12:14 PM on Wednesday, September 30th, 2020
Received a Purchase Order from a Toronto based film production company, Flatmate Productions Inc., a subsidiary of Cream Production Inc., to provide COVID-19 test kits and related screening solutions
Ontario is one of the largest production centres in North America, representing approximately 34% of Canadian based film productions
Ontario’s film and television industry had a record-breaking year in 2019, with 343 productions bringing in approximately $2.16 billion in production spending for the economy
Toronto, Ontario–(September 30, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that it received a Purchase Order (the “PO”) from a Toronto based film production company, Flatmate Productions Inc., a subsidiary of Cream Production Inc., to provide COVID-19 test kits and related screening solutions.
“With Toronto based production companies resuming to filming their projects, we feel that film production companies will be an important market for the Company to sell its COVID-19 tests and related services as Toronto is one of the largest film production locations in North America,” commented Marshall Gunter CEO of the Company.
In this respect, Ontario is one of the largest production centres in North America, representing approximately 34% of Canadian based film productions. Ontario’s film and television industry had a record-breaking year in 2019, with 343 productions bringing in approximately $2.16 billion in production spending for the economy. (Source: Government of Ontario: Record-breaking Year for Ontario’s Film and Television Industry)
Datametrex anticipates that it will have little or no upfront costs associated with importing and selling these test kits pursuant to the terms of the PO.
About Cream
Cream is a Toronto and LA based creative production company. They deliver distinctive and top-rated content to television and digital platforms around the world including Netflix, CNN, Hulu, PBS, Discovery Channel, History Channel, and the BBC. Additional information on Cream is available at www.creamproductions.com
About Datametrex
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact: Marshall Gunter: CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.
Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.
Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
